Regulatory Watch
June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022 June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022

About PeptideExaminer

PeptideExaminer exists because the peptide market has a trust problem — and nobody without a conflict of interest was solving it.

The Problem

Search for information about any peptide and you'll find the same landscape: vendor blogs disguised as educational content, affiliate sites ranking "Top 10 Vendors" based on commission rates, forums with vendor sponsorships, and testing companies whose business model creates incentives to surface bad results.

Everyone writing about peptides is selling peptides — or getting paid by someone who does.

Meanwhile, consumers spending $100-$200/month on peptide products have no reliable way to evaluate vendor claims, understand what the research actually supports, or distinguish marketing from science.

Our Approach

PeptideExaminer is an independent analysis platform. We don't sell peptides. We don't accept vendor sponsorship. We don't publish pay-for-play reviews.

What we do: dig into the research, analyze the data, evaluate the vendors, and tell you what we find — including when the honest answer is "we don't know."

Our analysis combines primary research review (reading the actual studies, not vendor summaries of studies), public testing data analysis, regulatory enforcement tracking, and vendor transparency evaluation using a consistent, documented methodology.

Editorial Independence

We earn revenue through display advertising and clearly-disclosed affiliate links. Our editorial and revenue operations are completely separated. Read our full disclosure policy.

Contact

General inquiries: hello@peptideexaminer.com
Tips and corrections: tips@peptideexaminer.com
Ethics and editorial: ethics@peptideexaminer.com